Malidi Ahamadi, Nitin Mehrotra, Nathan Hanan, Ka Lai Yee, Ferdous Gheyas, Judith Anton, Massimo Bani, Babak Boroojerdi, Hans Smit, Jonas Weidemann, Sreeraj Macha, Vincent Thuillier, Chao Chen, Minhua Yang, Caroline H Williams-Gray, Glenn T Stebbins, Gennaro Pagano, Yaming Hang, Kenneth Marek, Charles S Venuto, Monica Javidnia, David Dexter, Anne Pedata, Bob Stafford, Mussie Akalu, Diane Stephenson, Klaus Romero, Vikram Sinha
Leucine-rich repeat kinase 2 (LRRK2) inhibitors are currently in clinical development as interventions to slow progression of Parkinson's disease (PD). Understanding the rate of progression in PD as measured by both motor and non-motor features is particularly important in assessing the potential therapeutic effect of LRRK2 inhibitors in clinical development. Using standardized data from the Critical Path for Parkinson's Unified Clinical Database, we quantified the rate of progression of the Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part I (non-motor aspects of experiences of daily living) in 158 PD participants who were carriers and 598 PD participants who were non-carriers of at least one of three different LRRK2 gene mutations (G2019S, R1441C/G, R1628P)...
April 24, 2021: Clinical Pharmacology and Therapeutics